<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mycopathologia</journal-id><journal-id journal-id-type="iso-abbrev">Mycopathologia</journal-id><journal-title-group><journal-title>Mycopathologia</journal-title></journal-title-group><issn pub-type="ppub">0301-486X</issn><issn pub-type="epub">1573-0832</issn><publisher><publisher-name>Springer Netherlands</publisher-name><publisher-loc>Dordrecht</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40186715</article-id><article-id pub-id-type="pmc">PMC11972221</article-id>
<article-id pub-id-type="publisher-id">941</article-id><article-id pub-id-type="doi">10.1007/s11046-025-00941-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Trends of Azole-Resistant <italic>Aspergillus</italic> Fumigatus Susceptibility Over 12 Years from a German ECMM Excellence Center</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5601-2444</contrib-id><name><surname>Verhasselt</surname><given-names>Hedda Luise</given-names></name><address><email>hedda-luise.verhasselt@uk-essen.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Thissen</surname><given-names>Lara</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Scharmann</surname><given-names>Ulrike</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dittmer</surname><given-names>Silke</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rath</surname><given-names>Peter-Michael</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Steinmann</surname><given-names>Joerg</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kirchhoff</surname><given-names>Lisa</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04mz5ra38</institution-id><institution-id institution-id-type="GRID">grid.5718.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2187 5445</institution-id><institution>Institute of Medical Microbiology, Excellence Center for Medical Mycology (ECMM), </institution><institution>University Hospital Essen, University of Duisburg-Essen, </institution></institution-wrap>Virchowstra&#x000df;e 179, 45147 Essen, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/010qwhr53</institution-id><institution-id institution-id-type="GRID">grid.419835.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 0729 8880</institution-id><institution>Institute of Clinical Microbiology, Infectious Diseases and Infection Control, Klinikum N&#x000fc;rnberg, </institution><institution>Paracelsus Medical University, </institution></institution-wrap>Nuremberg, Germany </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>190</volume><issue>2</issue><elocation-id>34</elocation-id><history><date date-type="received"><day>13</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Numbers of infections with azole-resistant <italic>Aspergillus fumigatus</italic> (ARAf) were rising in the last decades. We assessed ARAf susceptibility trends towards five antifungal agents (amphotericin B (AMB), itraconazole (ITR), voriconazole (VCZ), olorofim (OLO) and manogepix (MGX)) over twelve&#x000a0;years in a German Excellence Center for Medical Mycology (ECMM). In addition, underlying mutations were studied and correlated with trends in minimum inhibitory concentration (MIC). Broth microdilution (BMD) was performed following EUCAST guidelines for 143 clinical ARAf isolates collected between the years 2011 and 2022 in a West German tertiary care centre. BMD was carried out for all antifungal agents in the following concentration ranges: 0.016&#x02013;8&#x000a0;mg/L for AMB, ITR and VCZ as well as 0.001&#x02013;0.5&#x000a0;mg/L for OLO and 0.004&#x02013;2&#x000a0;mg/L for MGX. Molecular assays on mutations associated with antifungal resistance were performed for all 143 isolates (AsperGenius&#x000ae; 1.0, Pathonostics, Maastricht, The Netherlands) and for a total of ten non TR<sub>34</sub>/L98H and TR<sub>46</sub>/Y121F/T289A mutated ARAf isolates additional <italic>cyp51A</italic> sequencing was carried out. For all isolates, microdilution revealed a MIC<sub>50</sub> of&#x02009;&#x0003e;&#x02009;8&#x000a0;mg/L for ITR, 4&#x000a0;mg/L for VCZ, 0.03&#x000a0;mg/L for OLO, 0.016&#x000a0;mg/L for MGX, and 0.5&#x000a0;mg/L for AMB. Considering EUCAST breakpoints, 97.9% of the strains (n&#x02009;=&#x02009;140) were resistant to VCZ, 1.4% (n&#x02009;=&#x02009;2) towards AMB and 92.3% towards ITR (n&#x02009;=&#x02009;132). Molecular assays revealed 123 (86%) isolates with the azole resistance underlying mutation TR<sub>34</sub>/L98H, 10 (7%) with a TR<sub>46</sub>/Y121F/T289A mutation and 10 (7%) with other <italic>cyp51A</italic> mutations. A comparison of triazole MICs of isolates collected from 2011 to 2019 with the MICs of isolates collected between 2020 and 2022 revealed no significant differences for itraconazole (<italic>p</italic>&#x02009;=&#x02009;0.543) and for voriconazole (<italic>p</italic>&#x02009;=&#x02009;0.148),with a trend of increased geometric mean for ITR and VCZ MICs over time. MICs for OLO and MGX did not significantly differ between isolates with the distinct azole-resistance underlying mutations. Before 2016, the azole resistance underlying mutations were mainly TR<sub>34</sub>/L98H, but the portion of isolates with TR<sub>46</sub>/Y121F/T289A and other <italic>Cyp51A</italic> mutated isolates increased afterwards. We showed almost stable MICs for ITR and VCZ over twelve years in ARAf isolates from West Germany while occurring azole resistance underlying mutations varied with an increase in the proportion of TR<sub>46</sub>/Y121F/T289A and other <italic>Cyp51A</italic> mutations after 2016.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd><italic>Aspergillus</italic></kwd><kwd>Azole-resistance</kwd><kwd>Manogepix</kwd><kwd>Olorofim</kwd><kwd><italic>CYP51A</italic></kwd></kwd-group><funding-group><award-group><funding-source><institution>Universit&#x000e4;tsklinikum Essen (8912)</institution></funding-source></award-group><open-access><p>Open Access funding enabled and organized by Projekt DEAL.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature B.V. 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Mould infections are a public health concern posing globally crucial disease burden with considerable mortality rates ranging from 30 to 80% [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. <italic>Aspergillus fumigatus</italic> is the most common cause of aspergillosis, with rising rates of infections, partly due to increasing numbers of immunocompromised patients [<xref ref-type="bibr" rid="CR3">3</xref>]. The significance of azole-resistance, first described in the 1990s [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>], raised in the last years [<xref ref-type="bibr" rid="CR6">6</xref>] up to&#x02009;&#x0003e;&#x02009;10% in some centers [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Today, azole resistance in <italic>A.&#x000a0;fumigatus</italic> is known to harbour a high priority for choosing the right treatment option.</p><p id="Par3">Azole-resistance in <italic>A. fumigatus</italic> is acquired, and mainly occurs via tandem repeat mutations in the promoter region of the <italic>cyp51A</italic> gene in addition to amino acid substitution(s). <italic>Cyp51A</italic> encodes the enzymatic target of azole drugs, namely the sterol 14-alpha demethylase that plays a critical role in the ergosterol biosynthesis pathway of <italic>A. fumigatus</italic> [<xref ref-type="bibr" rid="CR9">9</xref>]. The most frequently described azole-resistance underlying mutations of this gene are TR<sub>34</sub>/L98H and TR<sub>46</sub>/Y121F/T289A [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par4">Early systemic antifungal treatment is crucial for patient outcome. The conventional treatment option for systemic infections with <italic>A. fumigatus</italic> such as invasive pulmonary aspergillosis (IPA) are triazoles, e.g. isavuconazole or voriconazole (VCZ). Liposomal amphotericin B (AMB) is another treatment option. While triazole treatment got challenging due to the upcoming of increased azole resistances, <italic>Aspergillus</italic> remained widely sensitive against treatment with liposomal AMB [<xref ref-type="bibr" rid="CR11">11</xref>]. However, recently reported increasing AMB minimum inhibitory concentrations (MICs) of roughly 40% of Brazilian <italic>A. fumigatus</italic> isolates being resistant reveals more than ever the need for novel treatment options [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par5">Several novel antifungal agents are on the rise. Fosmanogepix, the N-phosphonooxymethylene prodrug from the active moiety manogepix (MGX), previously showed good activity against a broad range of human pathogenic moulds and yeasts, among them <italic>Aspergillus</italic> [<xref ref-type="bibr" rid="CR13">13</xref>]. MGX is a pyridine-isoxazole based antifungal, targeting enzymatic post-translational modification of proteins in fungi. Olorofim (OLO), former F901318, is the first drug of the new class of orotomides, targeting the pyrimidine biosynthesis. There is promising data on OLO activity against moulds, even though the FDA declined the first application of olorofim for treatment of rare mould infections in 2023 [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par6">We here assessed the activity of AMB, itraconazole (ITR), OLO, MGX, and VCZ over time in a German ECMM Excellence Center against a total of 143 azole resistant <italic>A. fumigatus</italic> (ARAf) strains.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Isolates</title><p id="Par7">The study did not include patients` details and did not result in additional constraints for patients. All data were anonymously analysed without patient consent owing to the retrospective nature of the study. All procedures and methods were carried out in accordance with approved guidelines. The isolates included in this study comprised a total of 143 clinical ARAf strains, collected between the years 2011 and 2022 (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) at the ECMM Excellence Center, University Hospital Essen, Germany. Entry criterion for all isolates was growth on sabouraud dextrose agar containing 4&#x000a0;mg/L ITR [<xref ref-type="bibr" rid="CR15">15</xref>] as well as minimum inhibitory concentrations of itraconazole and voriconazole&#x02009;&#x0003e;&#x02009;1&#x000a0;mg/L proven by MIC gradient test. The species had been identified by characteristic micro- and macro-morphology as well as in parts by &#x003b2;-tubulin or ITS-sequencing as described previously [<xref ref-type="bibr" rid="CR15">15</xref>]. All isolates were frozen at -80&#x000a0;&#x000b0;C until further use and are listed in supplementary Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Number of strains collected per year. One isolate per patient</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Year</th><th align="left">N</th></tr></thead><tbody><tr><td align="left">2011</td><td char="." align="char">2</td></tr><tr><td align="left">2012</td><td char="." align="char">18</td></tr><tr><td align="left">2013</td><td char="." align="char">12</td></tr><tr><td align="left">2014</td><td char="." align="char">7</td></tr><tr><td align="left">2015</td><td char="." align="char">12</td></tr><tr><td align="left">2016</td><td char="." align="char">12</td></tr><tr><td align="left">2017</td><td char="." align="char">9</td></tr><tr><td align="left">2018</td><td char="." align="char">10</td></tr><tr><td align="left">2019</td><td char="." align="char">8</td></tr><tr><td align="left">2020</td><td char="." align="char">17</td></tr><tr><td align="left">2021</td><td char="." align="char">26</td></tr><tr><td align="left">2022</td><td char="." align="char">10</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title>Broth Microdilution (BMD) Assay</title><p id="Par8">BMD was carried out according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommendations (E.DEF 9.4) for determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds [<xref ref-type="bibr" rid="CR16">16</xref>] for all 143 isolates. AMB (Sigma-Aldrich, St. Louis, MO, USA), MGX (APX001A; InvivoChem, Libertyville, IL, USA), ITR (Sigma-Aldrich), OLO (F901318; Hycultec, Beutelsbach, Germany), VCZ (Sigma-Aldrich) were diluted in solvent [dimethyl sulfoxide (DMSO)] and RPMI&#x02009;+&#x02009;MOPS [3-(N -morpholino)propanesulfonic acid] (2% glucose) for the preparation of stock solutions. The concentration ranges for the BMD assay are stated in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. MICs or respectively minimum effective concentrations (MECs) were determined as cut-off values for each isolate after 48&#x000a0;h of incubation at 34 to 37&#x000a0;&#x000b0;C in ambient air. MICs were defined as the concentration yielding no discernible growth upon simple visual inspection [<xref ref-type="bibr" rid="CR17">17</xref>]. MGX MECs were read using a confocal microscope as recommended by EUCAST [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. The MIC/MEC range, MIC<sub>50</sub>/MEC<sub>50</sub>, MIC<sub>90</sub>/MEC<sub>90</sub>, and geometric mean (GM) MIC/MEC were estimated. For calculation of GM, MIC values&#x02009;&#x0003e;&#x02009;8&#x000a0;mg/L were defined as 16&#x000a0;mg/L.<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Test ranges (mg/L) in broth microdilution for the five included antifungal agents</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">AMB</th><th align="left">ITR</th><th align="left">MGX</th><th align="left">OLO</th><th align="left">VCZ</th></tr></thead><tbody><tr><td align="left">0.016&#x02013;8</td><td align="left">0.016&#x02013;8</td><td char="." align="char">0.004&#x02013;2</td><td char="." align="char">0.001&#x02013;0.5</td><td align="left">0.016&#x02013;8</td></tr></tbody></table><table-wrap-foot><p>AMB, Amphotericin B; ITR, Itraconazole; MGX, Manogepix; OLO, Olorofim; VCZ, Voriconazole</p></table-wrap-foot></table-wrap></p><p id="Par9">As a quality control, <italic>A. fumigatus</italic> reference strain ATCC 204305 was included. For data interpretation, the breakpoint table version 10.0 provided by EUCAST was applied [<xref ref-type="bibr" rid="CR19">19</xref>]. Breakpoints were used to interpret MICs obtained for AMB, ITR and VCZ, as no breakpoints are available for the other included agents.</p></sec><sec id="Sec5"><title>DNA Isolation</title><p id="Par10">From Sabouraud dextrose agar inoculated with the isolate, three 5&#x000a0;mm<sup>2</sup> agar blocks were punched out and lysed using MagNA Lyser (Roche, Basel, Switzerland). For total DNA extraction and purification, the Maxwell 16 instrument was used with the Maxwell 16 LEV Total RNA Purification Kit (Promega, Mannheim, Germany).</p></sec><sec id="Sec6"><title>Determination of Mutations in <italic>cyp51A</italic></title><p id="Par11">A commercially available multiplex real time PCR (AsperGenius&#x000ae; 1.0, Pathonostics, Maastricht, The Netherlands) was performed for all 143 isolates for detection of the most common mutations in <italic>cyp51A:</italic> TR<sub>34</sub>, L98H and Y121F/T289A.</p><p id="Par12">In cases without TR<sub>34</sub>, L98H and Y121F/T289A mutations the amplification of the <italic>cyp51A</italic>-gene was done with three distinct primer pairs (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). For those strains negative in the AsperGenius&#x000ae; PCR, <italic>cyp51A</italic> gene was sequenced as described elsewhere [<xref ref-type="bibr" rid="CR20">20</xref>]. Amplification for these strains were followed by aligning of sequences in the FunResDB, a web-resourced database by the <italic>Nationales Referenzzentrum f&#x000fc;r invasive Pilzinfektionen</italic> (NRZMyk, Jena, Germany) for genotypic susceptibility testing of <italic>A. fumigatus</italic> [<xref ref-type="bibr" rid="CR21">21</xref>]. The sequences were matched with the non-mutated <italic>cyp51A</italic> sequence.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Sequences of three primer pairs used for PCR. Primers were used in concentration of 50&#x000a0;&#x000b5;M, the final concentration was 12.5&#x000a0;&#x000b5;M</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Primer</th><th align="left">Forward primer sequence</th><th align="left">Reverse primer sequence</th></tr></thead><tbody><tr><td align="left">CYP1</td><td align="left">5&#x02019;-CACCCTCCCTGTGTCTCCT-3&#x02019;</td><td align="left">5&#x02019;-AGCCTTGAAAGTTCGGTGAA-3&#x02019;</td></tr><tr><td align="left">CYP2</td><td align="left">5&#x02019;-CATGTGCCACTTATTGAGAAGG-3&#x02019;</td><td align="left">5&#x02019;-CCTTGCGCATGATAGAGTGA-3&#x02019;</td></tr><tr><td align="left">CYP3</td><td align="left">5&#x02019;-TTCCTCCGCTCCAGTACAAG-3&#x02019;</td><td align="left">5&#x02019;-CCTTTGAAGTCCTCGATGGT-3&#x02019;</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec7"><title>Results</title><p id="Par13">The here tested antifungal agents showed different activity against the ARAf strains. The obtained MIC<sub>50</sub>, MIC<sub>90</sub> values as well as the GM and range of MICs and MEC, respectively are listed for each tested antifungal drug in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>. Overall, the lowest MIC/MECs have been shown for MGX followed by OLO against the vast majority of included strains. Considering the clinical breakpoints provided by EUCAST, 1.4, 92.3 and 97.9% of the strains were resistant towards AMB, ITR, and VCZ, respectively.<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Minimum inhibitory/effective concentrations (mg/L) of ARAf (N&#x02009;=&#x02009;143) against five different antifungal agents</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">AMB</th><th align="left">ITR</th><th align="left">MGX*</th><th align="left">OLO</th><th align="left">VCZ</th></tr></thead><tbody><tr><td align="left">GM<sup>#</sup></td><td align="left">0.540</td><td align="left">10.664</td><td align="left">0.018</td><td align="left">0.029</td><td align="left">4.747</td></tr><tr><td align="left">Range</td><td align="left">0.125&#x02013;2</td><td align="left">0.5&#x02013;&#x0003e;&#x02009;8</td><td align="left">0.08&#x02013;0.06</td><td align="left">0.008&#x02013;0.125</td><td align="left">0.25&#x02013;&#x0003e;&#x02009;8</td></tr><tr><td align="left">MIC<sub>50</sub>/MEC<sub>50</sub></td><td align="left">0.5</td><td align="left">&#x02009;&#x0003e;&#x02009;8</td><td align="left">0.016</td><td align="left">0.03</td><td align="left">4</td></tr><tr><td align="left">MIC<sub>90</sub>/MEC<sub>90</sub></td><td align="left">1</td><td align="left">&#x02009;&#x0003e;&#x02009;8</td><td align="left">0.03</td><td align="left">0.06</td><td align="left">&#x02009;&#x0003e;&#x02009;8</td></tr></tbody></table><table-wrap-foot><p>AMB, Amphotericin B; ITR, Itraconazole; GM, Geometric mean; MGX, Manogepix; MEC<sub>50</sub>, Minimum effective concentration for at least 50% of strains; MEC<sub>90</sub>, Minimum effective concentration for at least 90% of strains; MIC<sub>50</sub>, Minimum inhibitory concentration for at least 50% of strains; MIC<sub>90</sub>, Minimum inhibitory concentration for at least 90% of strains; OLO, Olorofim; VCZ, Voriconazole. *MEC was determined for MGX. <sup>#</sup>When no detectable antifungal activity was observed at 8&#x000a0;mg/L a value of 16&#x000a0;mg/L was used to calculate the GM</p></table-wrap-foot></table-wrap></p><p id="Par14">A comparison of triazole MICs between the period from 2011 and 2019 compared with the MICs of isolates collected between 2020 and 2022 revealed no significant differences (<italic>p</italic>&#x02009;=&#x02009;0.534 for itraconazole and 0.148 for voriconazole, paired t test), with slightly increased GM value for both triazoles over time (GM itraconazole 2011&#x02013;2019&#x02009;=&#x02009;10.6&#x000a0;mg/L; 2020&#x02013;2022&#x02009;=&#x02009;10.9&#x000a0;mg/L and GM voriconazole 2011&#x02013;2019&#x02009;=&#x02009;4.7&#x000a0;mg/L; 2020&#x02013;2022&#x02009;=&#x02009;4.9&#x000a0;mg/L; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Geometric mean (GM) with 95% confidence interval of itraconazole (ITR) and voriconazole (VCZ) in mg/L against ARAf collected in the years 2011 to 2019 (blue, N&#x02009;=&#x02009;90)) and 2020&#x02013;2022 (red, N&#x02009;=&#x02009;53). When no detectable antifungal activity was observed at 8&#x000a0;mg/L a value of 16&#x000a0;mg/L was used to calculate the GM</p></caption><graphic xlink:href="11046_2025_941_Fig1_HTML" id="MO1"/></fig></p><p id="Par15">Molecular investigation of the strains revealed that the vast majority (86%) of ARAf strains have an underlying TR<sub>34</sub>/L98H mutation, followed by TR<sub>46</sub>/Y121F/T289A with 7% whereas 7% of strains harboured other <italic>cyp51A</italic>-associated point mutations. The identified non TR<sub>34</sub>/L98H and TR<sub>46</sub>/Y121F/T289A mutations are listed in Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>.<table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>Mutations detected in cyp51A sequencing for ARAf strains (N&#x02009;=&#x02009;10) without a TR<sub>34</sub>/L98H/TR<sub>46</sub>/Y121F/T289A mutation</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">ID</th><th align="left"/><th align="left">TR in DNA promoter</th><th align="left">Mutations</th></tr></thead><tbody><tr><td align="left">8</td><td align="left">1964</td><td align="left">NO</td><td align="left">G448S</td></tr><tr><td align="left">10</td><td align="left">1966</td><td align="left">NO</td><td align="left">F46Y, Y158D, L159R, M172V, I360F, H361L, L336F, E427K, K515R, *516R</td></tr><tr><td align="left">15</td><td align="left">1972</td><td align="left">No</td><td align="left">F46Y, D157P, S168K, H147P, L150P, M172V, N248T, D255E, M368L, R369N, K370L, K372I, E427K</td></tr><tr><td align="left">20</td><td align="left">1979</td><td align="left">NO</td><td align="left">M4T, W6G, L7I, L159P, R160G, S168Q, S146L, H147P, L150P, M368R, V371E, L336F</td></tr><tr><td align="left">87</td><td align="left">2344</td><td align="left">NO</td><td align="left">K153N, E154D, L156F, D157C, Y158N, H285Y, S362I, V371E, L336F, L347R, P348S</td></tr><tr><td align="left">106</td><td align="left">2488</td><td align="left">NO</td><td align="left">L7D, K153N, E154P, V155L, D157G, S168*, E154R, P163T, P216H, I364H, V371G, L336F, K515R, *516R</td></tr><tr><td align="left">167</td><td align="left">2795</td><td align="left">NO</td><td align="left">N164T</td></tr><tr><td align="left">183</td><td align="left">M328</td><td align="left">NO</td><td align="left">M1K, L7I, G54W, V155E, Y158L, Q166K, S168*, D157S, L159Q, R160A, D161N, S162C, P163T, T357P, H361Y, S362V, V371E, L336F, K346Q, K511I, K515R, *516R</td></tr><tr><td align="left">189</td><td align="left">M414</td><td align="left">NO</td><td align="left">L7V, V13I, R160C, S168*, Y158S, S162A, R369G, L336F, K511I, K515R, *516R</td></tr><tr><td align="left">208</td><td align="left">M923</td><td align="left">NO</td><td align="left">V155A, V155S, R369A, L336F, P348S, T513N</td></tr></tbody></table><table-wrap-foot><p>TR, Tandem repeat</p></table-wrap-foot></table-wrap></p><p id="Par16">Concerning the azole resistance underlying mutations, the activity of AMB, ITR and VCZ did significantly differ (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A&#x02013;F). While VCZ did exhibit highest MICs against strains with mutations in TR<sub>46</sub>/Y121F/T289A, ITR did show significantly higher MICs towards the isolates with a TR<sub>34</sub>/L98H mutation. Even though, nearly all (97.9%) of the strains included in this analysis showed a VCZ resistance phenotype and 92.3% exhibited resistance to ITR according to EUCAST breakpoints. While four isolates (40%) with a TR<sub>46</sub>/Y121F/T289A mutation were susceptible towards ITR (MIC of 0.5&#x000a0;mg/L), only 5.7% of the TR<sub>34</sub>/L98H harbouring strains were susceptible against ITR. VCZ showed MICs&#x02009;&#x02265;&#x02009;8&#x000a0;mg/L for all of the strains with TR<sub>46</sub> mutation whereas the GM of MICs against the strains harbouring a TR<sub>34</sub>/L98H mutation was 4.5&#x000a0;mg/L. Only two (20%) strains (ID 106 and 183) with other mutations were susceptible towards VCZ (GM&#x02009;=&#x02009;0.25&#x000a0;mg/L). For these strains, concordant mutations were S168*, P163T, L336F, K515R and *516R. For the novel antifungal agents MGX and OLO, no significant difference in activity against strains with distinct mutations has been noticed (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>D&#x02013;E).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Geometric Mean (GM) with 95% Confidence interval of <bold>a</bold> minimum inhibition concentration (MIC) of amphotericin B (AMB), <bold>b</bold> MIC of itraconazole (ITR), <bold>c</bold> MEC of manogepix (MGX), <bold>d</bold> MIC of olorofim (OLO) and <bold>e</bold> MIC of voriconazole (VCZ) towards A. fumigatus isolates with distinct underlying mutations: TR<sub>34</sub>/L98H (N&#x02009;=&#x02009;123), TR<sub>46</sub>/Y121F/T289A (N&#x02009;=&#x02009;10) and other unknown mutations (N&#x02009;=&#x02009;10). Statistical test: ordinary one-way ANOVA. Significance was assumed when <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05. *: <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05; **** <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001. When no detectable antifungal activity was observed at 8&#x000a0;mg/L a value of 16&#x000a0;mg/L was used to calculate the GM</p></caption><graphic xlink:href="11046_2025_941_Fig2_HTML" id="MO2"/></fig></p><p id="Par17">Over time, the occurring azole resistance underlying mutations in the collected ARAf strains varied (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). While nearly all strains from clinical specimen before 2016 were TR<sub>34</sub>/L98H strains, the portion of strains with TR<sub>46</sub>/Y121F/T289A and other <italic>cyp51A</italic> mutated strains increased after that.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Prevalence of azole resistance underlying mutation in the included <italic>A. fumigatus</italic> strains over time</p></caption><graphic xlink:href="11046_2025_941_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec8"><title>Discussion</title><p id="Par18">In this study, a total of 143 ARAf strains from a German ECMM excellence centre were analysed on their susceptibility towards the commonly used triazoles ITR and VCZ as well as AMB and the novel antifungal agents OLO and MGX. The findings for antifungal activity in BMD was overall good for all two tested novel agents, without significant differences in susceptibility of ARAf strains with distinct underlying mutations. The activity of the two novel drugs were additionally higher compared to those of the azoles and AMB on an mg/L basis.</p><p id="Par19">In the Netherlands, the rates of azole resistance showed a declining trend over the past years, with varying frequency in individual centers, with the most common found mutation in TR<sub>34</sub> [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>], going along with the here described results. Sequencing of isolates revealed most isolates harbouring the TR<sub>34</sub>/L98H mutation in the <italic>cyp51A</italic> gene. This is a 34-base pair tandem repeat and additionally a change of &#x02018;L&#x02019; to &#x02018;H&#x02019; at position 98. This mutation was rapidly emerging, especially in the Netherlands, but now has been increasingly identified in other, also non-European countries [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Whereas isolates from The Netherlands, Taiwan, Denmark, Brazil and China were genetically similar, TR<sub>34</sub>/L98H strains from e.g. the Middle East are genotypically distinct from the European isolates, indicating no simple geographical spread [<xref ref-type="bibr" rid="CR26">26</xref>]. However, other more recently published studies indicate high levels of similarities between isolates from the Netherlands, Taiwan, Denmark, Brazil, and China [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par20">Risk factor for acquisition of infections with ARAf are e.g. presence and treatment of chronic <italic>Aspergillus</italic> infections, and a linked high fungal burden, and prolonged azole exposure [<xref ref-type="bibr" rid="CR27">27</xref>]. Infections with ARAf isolates have been described to occur by two different routes, the development in situ in the lungs or by acquisition from the environment, potentially in parts driven by triazole use in agriculture [<xref ref-type="bibr" rid="CR27">27</xref>]. The presence of TR<sub>34</sub> and TR<sub>46</sub> is indicating an acquisition from the environment, rather than the in-host resistance development [<xref ref-type="bibr" rid="CR22">22</xref>]. Although this could not be proven in a recent publication [<xref ref-type="bibr" rid="CR28">28</xref>]. In a study from 2021, ten isolates (2.5%) were non-WT to ITR and six of these were additionally non-WT to VCZ. Accordingly to our findings, Pfaller et al. found the most common substitution in <italic>Cyp51A</italic> being TR<sub>34</sub>/L98H [<xref ref-type="bibr" rid="CR29">29</xref>]. A TR<sub>53</sub> mutated strain could not been found in the here included strains. For the two voriconazole susceptible strains with other mutations current literature did not provide specific information about the mutations found in relation to voriconazole susceptibility.</p><p id="Par21"><italic>A. fumigatus</italic> has been identified as the most common fungal pathogen occurring in critically ill COVID-19 patients and the prevalence of fungal drug resistance in patients suffering COVID-19 is generally high [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>]. Here, the comparison of the MICs of both azoles against isolated ARAfs from clinical specimens in the pre-COVID-19 period from 2011 to 2019 and the post-COVID-19 era between 2020 and 2022 revealed no significant differences in GM MICs. However, a trend of increasing MICs of both azoles could be detected. In contrast, the Dutch surveillance network reported a decreasing trend in the mean VCZ MIC values amongst <italic>A. fumigatus</italic> isolates harbouring the TR<sub>34</sub>/L98H mutation from 8&#x000a0;mg/L in 2013 to 2&#x000a0;mg/L in 2018 and the resistance rates towards VCZ declined around 34% in this time [<xref ref-type="bibr" rid="CR23">23</xref>]. Here, comparing the GM MICs of VCZ against pre- and post-COVID isolated ARAFs with a TR<sub>34</sub>/L98H mutation, an increasing trend without statistical significance could be detected.</p><p id="Par22">Notably, the here obtained MIC data of both triazoles against <italic>A. fumigatus</italic> revealed significantly higher MICs of VCZ against strains with a TR<sub>46</sub>/Y121F/T289A in <italic>cyp51A</italic> compared to TR<sub>34</sub>/L98H<sub>,</sub> whereas in case of ITR, higher MICs were found against strains with a TR<sub>34</sub>/L98H mutation. The differences in susceptibility phenotypes with regard to the underlying mutations and its specific combinations was beforehand described in literature [<xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>]. As a limitation resulting from the selected PCR for detection of mutations, our study did not search for additional mutations, which are simultaneously present together with TR<sub>46</sub>/Y121F/T289A and TR<sub>34</sub>/L98H, e.g. G448S. Although isolates with several azole resistance underlying mutations are mainly found in the environment [<xref ref-type="bibr" rid="CR37">37</xref>] than within patients&#x02019; settings [<xref ref-type="bibr" rid="CR38">38</xref>], our diagnostic approach might have missed other mutations. Another limitation is that no total numbers of ARAf and wildtype <italic>A. fumigatus</italic> isolates from the same period were given to build proportions in order to compare our findings with other countries.</p><p id="Par23">MGX has previously been demonstrated to be active against a broad range of human fungal pathogens, including <italic>Candida</italic> spp., difficult-to-treat rare moulds as <italic>Scedosporium</italic> spp. and <italic>Aspergillus</italic> spp. [<xref ref-type="bibr" rid="CR39">39</xref>&#x02013;<xref ref-type="bibr" rid="CR43">43</xref>]. In a study on 397 <italic>A. fumigatus</italic> isolates analysed in CLSI broth microdilution method, MEC<sub>50</sub> of 0.015&#x000a0;mg/L, MEC<sub>90</sub> of 0.03&#x000a0;mg/L was determined for MGX [<xref ref-type="bibr" rid="CR29">29</xref>]. The determined MEC<sub>50</sub> and MEC<sub>90</sub> values are corresponding to the data we collected. Additionally, MGX susceptibility did not differ between wild type <italic>A. fumigatus</italic> and ARAf strains as described by Pfaller et al<italic>.</italic> and has been described to have similar activity compared to echinocandins against <italic>A. fumigatus</italic>. In this study on 379 <italic>A. fumigatus</italic> strains, a wild-type upper limit (WT-UL) MECs of&#x02009;&#x02264;&#x02009;0.06&#x000a0;mg/L was defined for MGX [<xref ref-type="bibr" rid="CR29">29</xref>]. Using this as an epidemiological cut-off value (ECOFF) equivalent for the here generated data, 2.1% (N&#x02009;=&#x02009;3) of the ARAf strains were non-wild-type towards MGX. In contrast, 100% of the <italic>A. fumigatus</italic> strains assessed by Pfaller et al. were MGX wild-type [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par24">OLO has been demonstrated to exhibit activity against various moulds, including <italic>A. fumigatus</italic> wild type and ARAf [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. In a study from 2020 on 25 ARAf isolates, a MIC range from&#x02009;&#x02264;&#x02009;0.008&#x02013;0.032&#x000a0;mg/L was detected which is lower than the here defined highest MIC of 0.125&#x000a0;mg/L [<xref ref-type="bibr" rid="CR44">44</xref>]. Other studies found MICs between 0.016 and 0.25&#x000a0;mg/L [<xref ref-type="bibr" rid="CR45">45</xref>&#x02013;<xref ref-type="bibr" rid="CR47">47</xref>]. No difference in MIC distribution was detected between azole-susceptible and-resistant isolates [<xref ref-type="bibr" rid="CR45">45</xref>]. An assessment of 975 clinical <italic>A. fumigatus</italic> isolates revealed no intrinsic OLO resistance. In contrast, high numbers of conidia and olorofim exposure could force acquired OLO resistant phenotypes (MICs&#x02009;&#x0003e;&#x02009;8&#x000a0;mg/L) under laboratory conditions. This frequency of acquired resistance was shown to be lower than that for ITR but higher than for VCZ. The authors were furthermore capable to identify several amino acid substitutions in the <italic>PyrE</italic> gene with high rates at G119V [<xref ref-type="bibr" rid="CR48">48</xref>]. In a study on OLO antifungal activity, a WT-UL value of 0.03&#x000a0;mg/L was determined for <italic>A. fumigatus </italic>sensu lato strains [<xref ref-type="bibr" rid="CR49">49</xref>]. In another study on OLO activity against 1032 <italic>A. fumigatus</italic> isolates, a WT-UL<sub>97.5</sub> of&#x02009;&#x02264;&#x02009;0.125&#x000a0;mg/L was defined [<xref ref-type="bibr" rid="CR45">45</xref>]. Taking this WT-UL value as an ECOFF equivalent, here one strain (0.7%) showed non wild-type olorofim MICs.</p><p id="Par25">In conclusion, ARAfs are still a threat for patients and face their treating physicians with therapeutic challenges. We found almost stable MICs for ITR and VCZ over twelve years in ARAf isolates from West Germany while occurring azole resistance underlying mutations varied with an increase in the proportion of TR46/Y121F/T289A and other Cyp51A mutations in ARAf iafter 2016. The novel antifungals showed excellent in vitro activity against all type of mutations.</p></sec></body><back><fn-group><fn><p>Handling Editor: Jannik Stemler.</p></fn><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank Andrea Hain, Laura-Isabel Korth and Dirk Schmidt for excellent technical assistance.</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Silke Dittmer, Lara Thissen, Lisa Kirchhoff, Hedda Luise Verhasselt, Ulrike Scharmann, Peter-Michael Rath, and J&#x000f6;rg Steinmann. The first draft of the manuscript was written by Lisa Kirchhoff, Hedda Verhasselt, J&#x000f6;rg Steinmann and Peter-Michael Rath and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding enabled and organized by Projekt DEAL. The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par26">The authors have no relevant financial or non-financial interests to disclose.</p></notes><notes id="FPar2"><title>Ethical Approval</title><p id="Par27">The study did not include patient&#x02019;s details and did not result in additional constraints for patients. All data were anonymously analysed without patient consent owing to the retrospective nature of the study.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>KS</given-names></name><name><surname>Tsai</surname><given-names>CF</given-names></name><name><surname>Chen</surname><given-names>SC</given-names></name><name><surname>Huang</surname><given-names>WC</given-names></name></person-group><article-title>Clinical outcome and prognostic factors associated with invasive pulmonary aspergillosis: an 11-year follow-up report from Taiwan</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><issue>10</issue><fpage>e0186422</fpage><pub-id pub-id-type="pmid">29049319</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Sun KS, Tsai CF, Chen SC, Huang WC. Clinical outcome and prognostic factors associated with invasive pulmonary aspergillosis: an 11-year follow-up report from Taiwan. PLoS ONE. 2017;12(10): e0186422.<pub-id pub-id-type="pmid">29049319</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Legrand</surname><given-names>M</given-names></name><name><surname>Gits-Muselli</surname><given-names>M</given-names></name><name><surname>Boutin</surname><given-names>L</given-names></name><name><surname>Garcia-Hermoso</surname><given-names>D</given-names></name><name><surname>Maurel</surname><given-names>V</given-names></name><name><surname>Soussi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Detection of circulating mucorales DNA in critically Ill burn patients: preliminary report of a screening strategy for early diagnosis and treatment</article-title><source>Clin Infect Dis: Off Publ Infect Dis Soc Am</source><year>2016</year><volume>63</volume><issue>10</issue><fpage>1312</fpage><lpage>1317</lpage></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Legrand M, Gits-Muselli M, Boutin L, Garcia-Hermoso D, Maurel V, Soussi S, et al. Detection of circulating mucorales DNA in critically Ill burn patients: preliminary report of a screening strategy for early diagnosis and treatment. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2016;63(10):1312&#x02013;7.</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Cadena</surname><given-names>J</given-names></name><name><surname>Thompson</surname><given-names>GR</given-names><suffix>3rd</suffix></name><name><surname>Patterson</surname><given-names>TF</given-names></name></person-group><article-title>Aspergillosis: epidemiology, diagnosis, and treatment</article-title><source>Infect Dis Clin North Am</source><year>2021</year><volume>35</volume><issue>2</issue><fpage>415</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">34016284</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Cadena J, Thompson GR 3rd, Patterson TF. Aspergillosis: epidemiology, diagnosis, and treatment. Infect Dis Clin North Am. 2021;35(2):415&#x02013;34.<pub-id pub-id-type="pmid">34016284</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Dannaoui</surname><given-names>E</given-names></name><name><surname>Persat</surname><given-names>F</given-names></name><name><surname>Monier</surname><given-names>MF</given-names></name><name><surname>Borel</surname><given-names>E</given-names></name><name><surname>Piens</surname><given-names>MA</given-names></name><name><surname>Picot</surname><given-names>S</given-names></name></person-group><article-title>In-vitro susceptibility of <italic>Aspergillus</italic> spp. isolates to amphotericin B and itraconazole</article-title><source>J Antimicrob Chemother</source><year>1999</year><volume>44</volume><issue>4</issue><fpage>553</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">10588320</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Dannaoui E, Persat F, Monier MF, Borel E, Piens MA, Picot S. In-vitro susceptibility of <italic>Aspergillus</italic> spp. isolates to amphotericin B and itraconazole. J Antimicrob Chemother. 1999;44(4):553&#x02013;5.<pub-id pub-id-type="pmid">10588320</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Denning</surname><given-names>DW</given-names></name><name><surname>Venkateswarlu</surname><given-names>K</given-names></name><name><surname>Oakley</surname><given-names>KL</given-names></name><name><surname>Anderson</surname><given-names>MJ</given-names></name><name><surname>Manning</surname><given-names>NJ</given-names></name><name><surname>Stevens</surname><given-names>DA</given-names></name><name><surname>Warnock</surname><given-names>DW</given-names></name><name><surname>Kelly</surname><given-names>SL</given-names></name></person-group><article-title>Itraconazole resistance in Aspergillus fumigatus</article-title><source>Antimicrob Agents Chemother</source><year>1997</year><volume>41</volume><issue>6</issue><fpage>1364</fpage><lpage>1368</lpage><pub-id pub-id-type="doi">10.1128/AAC.41.6.1364</pub-id><pub-id pub-id-type="pmid">9174200</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, Stevens DA, Warnock DW, Kelly SL. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 1997;41(6):1364&#x02013;8. 10.1128/AAC.41.6.1364.<pub-id pub-id-type="pmid">9174200</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">WHO. WHO fungal priority pathogens list to guide research, development and public health action. 2022.</mixed-citation></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Buil</surname><given-names>JB</given-names></name><name><surname>Snelders</surname><given-names>E</given-names></name><name><surname>Denardi</surname><given-names>LB</given-names></name><name><surname>Melchers</surname><given-names>WJG</given-names></name><name><surname>Verweij</surname><given-names>PE</given-names></name></person-group><article-title>Trends in Azole Resistance in <italic>Aspergillus</italic> fumigatus, the Netherlands, 1994&#x02013;2016</article-title><source>Emerg Infect Dis</source><year>2019</year><volume>25</volume><issue>1</issue><fpage>176</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.3201/eid2501.171925</pub-id><pub-id pub-id-type="pmid">30561296</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Buil JB, Snelders E, Denardi LB, Melchers WJG, Verweij PE. Trends in Azole Resistance in <italic>Aspergillus</italic> fumigatus, the Netherlands, 1994&#x02013;2016. Emerg Infect Dis. 2019;25(1):176&#x02013;8. 10.3201/eid2501.171925.<pub-id pub-id-type="pmid">30561296</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Guegan</surname><given-names>H</given-names></name><name><surname>Prat</surname><given-names>E</given-names></name><name><surname>Robert-Gangneux</surname><given-names>F</given-names></name><name><surname>Gangneux</surname><given-names>JP</given-names></name></person-group><article-title>Azole Resistance in <italic>Aspergillus</italic> fumigatus: a five-year follow up experience in a tertiary hospital with a special focus on cystic fibrosis</article-title><source>Front Cell Infect Microbiol</source><year>2020</year><volume>10</volume><fpage>613774</fpage><pub-id pub-id-type="pmid">33680981</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Guegan H, Prat E, Robert-Gangneux F, Gangneux JP. Azole Resistance in <italic>Aspergillus</italic> fumigatus: a five-year follow up experience in a tertiary hospital with a special focus on cystic fibrosis. Front Cell Infect Microbiol. 2020;10: 613774.<pub-id pub-id-type="pmid">33680981</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Mellado</surname><given-names>E</given-names></name><name><surname>Garcia-Effron</surname><given-names>G</given-names></name><name><surname>Alc&#x000e1;zar-Fuoli</surname><given-names>L</given-names></name><name><surname>Melchers</surname><given-names>WJ</given-names></name><name><surname>Verweij</surname><given-names>PE</given-names></name><name><surname>Cuenca-Estrella</surname><given-names>M</given-names></name><etal/></person-group><article-title>A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations</article-title><source>Antimicrob Agents Chemother</source><year>2007</year><volume>51</volume><issue>6</issue><fpage>1897</fpage><lpage>1904</lpage><pub-id pub-id-type="pmid">17371828</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Mellado E, Garcia-Effron G, Alc&#x000e1;zar-Fuoli L, Melchers WJ, Verweij PE, Cuenca-Estrella M, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother. 2007;51(6):1897&#x02013;904.<pub-id pub-id-type="pmid">17371828</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Spiess</surname><given-names>B</given-names></name><name><surname>Postina</surname><given-names>P</given-names></name><name><surname>Reinwald</surname><given-names>M</given-names></name><name><surname>Cornely</surname><given-names>OA</given-names></name><name><surname>Hamprecht</surname><given-names>A</given-names></name><name><surname>Hoenigl</surname><given-names>M</given-names></name><etal/></person-group><article-title>Incidence of <italic>Cyp51</italic> a key mutations in <italic>Aspergillus</italic> fumigatus&#x02014;A study on primary clinical samples of immunocompromised patients in the period of 1995&#x02013;2013</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><issue>7</issue><fpage>e103113</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0103113</pub-id><pub-id pub-id-type="pmid">25072733</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Spiess B, Postina P, Reinwald M, Cornely OA, Hamprecht A, Hoenigl M, et al. Incidence of <italic>Cyp51</italic> a key mutations in <italic>Aspergillus</italic> fumigatus&#x02014;A study on primary clinical samples of immunocompromised patients in the period of 1995&#x02013;2013. PLoS ONE. 2014;9(7):e103113. 10.1371/journal.pone.0103113.<pub-id pub-id-type="pmid">25072733</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Jenks</surname><given-names>JD</given-names></name><name><surname>Hoenigl</surname><given-names>M</given-names></name></person-group><article-title>Treatment of Aspergillosis</article-title><source>J Fungi</source><year>2018</year><volume>4</volume><issue>3</issue><fpage>98</fpage><pub-id pub-id-type="doi">10.3390/jof4030098</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Jenks JD, Hoenigl M. Treatment of Aspergillosis. J Fungi. 2018;4(3):98. 10.3390/jof4030098.</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Reichert-Lima</surname><given-names>F</given-names></name><name><surname>Lyra</surname><given-names>L</given-names></name><name><surname>Pontes</surname><given-names>L</given-names></name><name><surname>Moretti</surname><given-names>ML</given-names></name><name><surname>Pham</surname><given-names>CD</given-names></name><name><surname>Lockhart</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Surveillance for Azoles Resistance in <italic>Aspergillus</italic> spp. highlights a high number of amphotericin B-resistant isolates</article-title><source>Mycoses</source><year>2018</year><volume>61</volume><fpage>360</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">29468746</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Reichert-Lima F, Lyra L, Pontes L, Moretti ML, Pham CD, Lockhart SR, et al. Surveillance for Azoles Resistance in <italic>Aspergillus</italic> spp. highlights a high number of amphotericin B-resistant isolates. Mycoses. 2018;61:360&#x02013;5.<pub-id pub-id-type="pmid">29468746</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>KJ</given-names></name><name><surname>Ibrahim</surname><given-names>AS</given-names></name></person-group><article-title>Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections</article-title><source>J Fungi</source><year>2020</year><volume>6</volume><issue>4</issue><fpage>239</fpage><pub-id pub-id-type="doi">10.3390/jof6040239</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Shaw KJ, Ibrahim AS. Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections. J Fungi. 2020;6(4):239. 10.3390/jof6040239.</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">F2G Receives Complete Response Letter from FDA for New Drug Application for Olorofim for The Treatment of Invasive Fungal Infections; Plans Resubmission With Additional Data and Analyses [press release]. <ext-link ext-link-type="uri" xlink:href="https://www.f2g.com/press_releases">https://www.f2g.com/press_releases</ext-link>: F2G2023.</mixed-citation></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Steinmann</surname><given-names>J</given-names></name><name><surname>Giraud</surname><given-names>S</given-names></name><name><surname>Schmidt</surname><given-names>D</given-names></name><name><surname>Sedlacek</surname><given-names>L</given-names></name><name><surname>Hamprecht</surname><given-names>A</given-names></name><name><surname>Houbraken</surname><given-names>J</given-names></name><etal/></person-group><article-title>Validation of a novel real-time PCR for detecting <italic>Rasamsonia argillacea</italic> species complex in respiratory secretions from cystic fibrosis patients</article-title><source>New Microb New Infect</source><year>2014</year><volume>2</volume><issue>3</issue><fpage>72</fpage><lpage>78</lpage></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Steinmann J, Giraud S, Schmidt D, Sedlacek L, Hamprecht A, Houbraken J, et al. Validation of a novel real-time PCR for detecting <italic>Rasamsonia argillacea</italic> species complex in respiratory secretions from cystic fibrosis patients. New Microb New Infect. 2014;2(3):72&#x02013;8.</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Guinea</surname><given-names>J</given-names></name><name><surname>Meletiadis</surname><given-names>J</given-names></name><name><surname>Arikan-Akdagli</surname><given-names>S</given-names></name><name><surname>Muehlethaler</surname><given-names>K</given-names></name><name><surname>Kahlmeter</surname><given-names>G</given-names></name><name><surname>Arendrup</surname><given-names>MC</given-names></name></person-group><article-title>Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds</article-title><source>EUCAST Definitive Doc EDef</source><year>2022</year><volume>9</volume><fpage>4</fpage></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Guinea J, Meletiadis J, Arikan-Akdagli S, Muehlethaler K, Kahlmeter G, Arendrup MC. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. EUCAST Definitive Doc EDef. 2022;9:4.</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Arendrup</surname><given-names>MC</given-names></name><name><surname>Meletiadis</surname><given-names>J</given-names></name><name><surname>Mouton</surname><given-names>JW</given-names></name><name><surname>Lagrou</surname><given-names>K</given-names></name><name><surname>Hamal</surname><given-names>P</given-names></name><name><surname>Guinea</surname><given-names>J</given-names></name><etal/></person-group><article-title>Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds</article-title><source>Eucast Definitive Doc EDef</source><year>2017</year><volume>9</volume><fpage>31</fpage></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Arendrup MC, Meletiadis J, Mouton JW, Lagrou K, Hamal P, Guinea J, et al. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. Eucast Definitive Doc EDef. 2017;9:31.</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>J&#x000f8;rgensen</surname><given-names>KM</given-names></name><name><surname>Astvad</surname><given-names>KMT</given-names></name><name><surname>Arendrup</surname><given-names>MC</given-names></name></person-group><article-title>In vitro activity of manogepix (APX001A) and comparators against contemporary molds: MEC comparison and preliminary experience with colorimetric MIC determination</article-title><source>Antimicrob Agents Chemother</source><year>2020</year><volume>64</volume><issue>8</issue><fpage>10</fpage><lpage>1128</lpage></element-citation><mixed-citation id="mc-CR18" publication-type="journal">J&#x000f8;rgensen KM, Astvad KMT, Arendrup MC. In vitro activity of manogepix (APX001A) and comparators against contemporary molds: MEC comparison and preliminary experience with colorimetric MIC determination. Antimicrob Agents Chemother. 2020;64(8):10&#x02013;1128.</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">The European Committee on Antimicrobial Susceptibility T. Breakpoint tables for interpretation of MICs for antifungal agents, version 10.0, 2020. Eucast. April 2020:0&#x02013;8.</mixed-citation></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Bu</surname><given-names>D</given-names></name><name><surname>Wan</surname><given-names>Z</given-names></name></person-group><article-title>Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma</article-title><source>J Antimicrob Chemother</source><year>2005</year><volume>55</volume><issue>1</issue><fpage>31</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">15563516</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Chen J, Li H, Li R, Bu D, Wan Z. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J Antimicrob Chemother. 2005;55(1):31&#x02013;7.<pub-id pub-id-type="pmid">15563516</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>M</given-names></name><name><surname>Schaer</surname><given-names>J</given-names></name><name><surname>Walther</surname><given-names>G</given-names></name><name><surname>Kaerger</surname><given-names>K</given-names></name><name><surname>Steinmann</surname><given-names>J</given-names></name><name><surname>Rath</surname><given-names>P-M</given-names></name><etal/></person-group><article-title>FunResDB&#x02014;A web resource for genotypic susceptibility testing of <italic>Aspergillus</italic> fumigatus</article-title><source>Med Mycol</source><year>2018</year><volume>56</volume><issue>1</issue><fpage>117</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">28340175</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Weber M, Schaer J, Walther G, Kaerger K, Steinmann J, Rath P-M, et al. FunResDB&#x02014;A web resource for genotypic susceptibility testing of <italic>Aspergillus</italic> fumigatus. Med Mycol. 2018;56(1):117&#x02013;20.<pub-id pub-id-type="pmid">28340175</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">National Institute for Public Health and the Environment tNS. NethMap 2023: Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands in 2022. 2023.</mixed-citation></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Lestrade</surname><given-names>PPA</given-names></name><name><surname>Buil</surname><given-names>JB</given-names></name><name><surname>van der Beek</surname><given-names>MT</given-names></name><name><surname>Kuijper</surname><given-names>EJ</given-names></name><name><surname>van Dijk</surname><given-names>K</given-names></name><name><surname>Kampinga</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Paradoxal trends in Azole-Resistant <italic>Aspergillus</italic> fumigatus in a national multicenter surveillance program, the Netherlands, 2013&#x02013;2018</article-title><source>Emerg Infect Dis</source><year>2020</year><volume>26</volume><issue>7</issue><fpage>1447</fpage><lpage>1455</lpage><pub-id pub-id-type="pmid">32568033</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Lestrade PPA, Buil JB, van der Beek MT, Kuijper EJ, van Dijk K, Kampinga GA, et al. Paradoxal trends in Azole-Resistant <italic>Aspergillus</italic> fumigatus in a national multicenter surveillance program, the Netherlands, 2013&#x02013;2018. Emerg Infect Dis. 2020;26(7):1447&#x02013;55.<pub-id pub-id-type="pmid">32568033</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuchido</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Nakano</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Matsumura</surname><given-names>Y</given-names></name><name><surname>Nagao</surname><given-names>M</given-names></name></person-group><article-title>Prospective multicenter surveillance of clinically isolated <italic>Aspergillus</italic> species revealed azole-resistant <italic>Aspergillus</italic> fumigatus isolates with TR34/L98H mutation in the Kyoto and Shiga regions of Japan</article-title><source>Med Mycol</source><year>2019</year><volume>57</volume><issue>8</issue><fpage>997</fpage><lpage>1003</lpage><pub-id pub-id-type="pmid">30690480</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Tsuchido Y, Tanaka M, Nakano S, Yamamoto M, Matsumura Y, Nagao M. Prospective multicenter surveillance of clinically isolated <italic>Aspergillus</italic> species revealed azole-resistant <italic>Aspergillus</italic> fumigatus isolates with TR34/L98H mutation in the Kyoto and Shiga regions of Japan. Med Mycol. 2019;57(8):997&#x02013;1003.<pub-id pub-id-type="pmid">30690480</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Pontes</surname><given-names>L</given-names></name><name><surname>Beraquet</surname><given-names>CAG</given-names></name><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Pigolli</surname><given-names>GL</given-names></name><name><surname>Lyra</surname><given-names>L</given-names></name><name><surname>Watanabe</surname><given-names>A</given-names></name><etal/></person-group><article-title><italic>Aspergillus</italic> fumigatus clinical isolates carrying <italic>CYP51A</italic> with TR34/L98H/S297T/F495I substitutions detected after four-year retrospective Azole Resistance screening in Brazil</article-title><source>Antimicrob Agents Chemother</source><year>2020</year><volume>64</volume><issue>3</issue><fpage>10</fpage><lpage>1128</lpage></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Pontes L, Beraquet CAG, Arai T, Pigolli GL, Lyra L, Watanabe A, et al. <italic>Aspergillus</italic> fumigatus clinical isolates carrying <italic>CYP51A</italic> with TR34/L98H/S297T/F495I substitutions detected after four-year retrospective Azole Resistance screening in Brazil. Antimicrob Agents Chemother. 2020;64(3):10&#x02013;1128.</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Vermeulen</surname><given-names>E</given-names></name><name><surname>Lagrou</surname><given-names>K</given-names></name><name><surname>Verweij</surname><given-names>PE</given-names></name></person-group><article-title>Azole resistance in Aspergillus fumigatus: a growing public health concern</article-title><source>Curr Opin Infect Dis</source><year>2013</year><volume>26</volume><issue>6</issue><fpage>493</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">24126719</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Vermeulen E, Lagrou K, Verweij PE. Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr Opin Infect Dis. 2013;26(6):493&#x02013;500.<pub-id pub-id-type="pmid">24126719</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>SJ</given-names></name><name><surname>Arendrup</surname><given-names>MC</given-names></name></person-group><article-title>Acquired antifungal drug resistance in <italic>Aspergillus</italic> fumigatus: epidemiology and detection</article-title><source>Med Mycol</source><year>2011</year><volume>49</volume><issue>Suppl 1</issue><fpage>S90</fpage><lpage>S95</lpage><pub-id pub-id-type="pmid">20795765</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Howard SJ, Arendrup MC. Acquired antifungal drug resistance in <italic>Aspergillus</italic> fumigatus: epidemiology and detection. Med Mycol. 2011;49(Suppl 1):S90&#x02013;5.<pub-id pub-id-type="pmid">20795765</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Barber</surname><given-names>AE</given-names></name><name><surname>Riedel</surname><given-names>J</given-names></name><name><surname>Sae-Ong</surname><given-names>T</given-names></name><name><surname>Kang</surname><given-names>K</given-names></name><name><surname>Brabetz</surname><given-names>W</given-names></name><name><surname>Panagiotou</surname><given-names>G</given-names></name><etal/></person-group><article-title>Effects of agricultural fungicide use on <italic>Aspergillus</italic> fumigatus abundance, antifungal susceptibility, and population structure</article-title><source>MBio</source><year>2020</year><volume>11</volume><issue>6</issue><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/mbio.02213-20</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Barber AE, Riedel J, Sae-Ong T, Kang K, Brabetz W, Panagiotou G, et al. Effects of agricultural fungicide use on <italic>Aspergillus</italic> fumigatus abundance, antifungal susceptibility, and population structure. MBio. 2020;11(6):10&#x02013;1128. 10.1128/mbio.02213-20.</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Pfaller</surname><given-names>MA</given-names></name><name><surname>Huband</surname><given-names>MD</given-names></name><name><surname>Flamm</surname><given-names>RK</given-names></name><name><surname>Bien</surname><given-names>PA</given-names></name><name><surname>Castanheira</surname><given-names>M</given-names></name></person-group><article-title>Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018&#x02013;2019)</article-title><source>J Glob Antimicrob Res</source><year>2021</year><volume>26</volume><fpage>117</fpage><lpage>127</lpage></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Pfaller MA, Huband MD, Flamm RK, Bien PA, Castanheira M. Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018&#x02013;2019). J Glob Antimicrob Res. 2021;26:117&#x02013;27.</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>CC</given-names></name><name><surname>Yu</surname><given-names>WL</given-names></name></person-group><article-title>COVID-19 associated with pulmonary aspergillosis: a literature review</article-title><source>J Microbiol Immunol Infect</source><year>2021</year><volume>54</volume><fpage>46</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">33012653</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Lai CC, Yu WL. COVID-19 associated with pulmonary aspergillosis: a literature review. J Microbiol Immunol Infect. 2021;54:46&#x02013;53.<pub-id pub-id-type="pmid">33012653</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Habibzadeh</surname><given-names>A</given-names></name><name><surname>Lankarani</surname><given-names>KB</given-names></name><name><surname>Farjam</surname><given-names>M</given-names></name><name><surname>Akbari</surname><given-names>M</given-names></name><name><surname>Kashani</surname><given-names>SMA</given-names></name><name><surname>Karimimoghadam</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Prevalence of fungal drug resistance in COVID-19 Infection: a global meta-analysis</article-title><source>Curr Fungal Infect Rep</source><year>2022</year><volume>16</volume><issue>4</issue><fpage>154</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">35990407</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Habibzadeh A, Lankarani KB, Farjam M, Akbari M, Kashani SMA, Karimimoghadam Z, et al. Prevalence of fungal drug resistance in COVID-19 Infection: a global meta-analysis. Curr Fungal Infect Rep. 2022;16(4):154&#x02013;64.<pub-id pub-id-type="pmid">35990407</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchhoff</surname><given-names>L</given-names></name><name><surname>Braun</surname><given-names>LM</given-names></name><name><surname>Schmidt</surname><given-names>D</given-names></name><name><surname>Dittmer</surname><given-names>S</given-names></name><name><surname>Dedy</surname><given-names>J</given-names></name><name><surname>Herbstreit</surname><given-names>F</given-names></name><etal/></person-group><article-title>COVID-19-associated pulmonary aspergillosis in ICU patients in a German reference centre: Phenotypic and molecular characterisation of <italic>Aspergillus</italic> fumigatus isolates</article-title><source>Mycoses</source><year>2022</year><volume>65</volume><fpage>458</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">35138651</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Kirchhoff L, Braun LM, Schmidt D, Dittmer S, Dedy J, Herbstreit F, et al. COVID-19-associated pulmonary aspergillosis in ICU patients in a German reference centre: Phenotypic and molecular characterisation of <italic>Aspergillus</italic> fumigatus isolates. Mycoses. 2022;65:458&#x02013;65.<pub-id pub-id-type="pmid">35138651</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Buil</surname><given-names>JB</given-names></name><name><surname>Hagen</surname><given-names>FA-O</given-names></name><name><surname>Chowdhary</surname><given-names>AA-O</given-names></name><name><surname>Verweij</surname><given-names>PE</given-names></name><name><surname>Meis</surname><given-names>JA-O</given-names></name></person-group><article-title>Itraconazole, voriconazole, and posaconazole CLSI MIC distributions for wild-type and azole-resistant <italic>Aspergillus</italic> fumigatus isolates</article-title><source>J Fungi</source><year>2018</year><volume>4</volume><issue>3</issue><fpage>103</fpage></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Buil JB, Hagen FA-O, Chowdhary AA-O, Verweij PE, Meis JA-O. Itraconazole, voriconazole, and posaconazole CLSI MIC distributions for wild-type and azole-resistant <italic>Aspergillus</italic> fumigatus isolates. J Fungi. 2018;4(3):103.</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>van Ingen</surname><given-names>J</given-names></name><name><surname>van der Lee</surname><given-names>HA</given-names></name><name><surname>Rijs</surname><given-names>TA</given-names></name><name><surname>Zoll</surname><given-names>J</given-names></name><name><surname>Leenstra</surname><given-names>T</given-names></name><name><surname>Melchers</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Azole, polyene and echinocandin MIC distributions for wild-type, TR34/L98H and TR46/Y121F/T289A Aspergillus fumigatus isolates in the Netherlands</article-title><source>J Antimicrob Chemother</source><year>2015</year><volume>70</volume><issue>1</issue><fpage>178</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">25301884</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">van Ingen J, van der Lee HA, Rijs TA, Zoll J, Leenstra T, Melchers WJ, et al. Azole, polyene and echinocandin MIC distributions for wild-type, TR34/L98H and TR46/Y121F/T289A Aspergillus fumigatus isolates in the Netherlands. J Antimicrob Chemother. 2015;70(1):178&#x02013;81.<pub-id pub-id-type="pmid">25301884</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Snelders</surname><given-names>E</given-names></name><name><surname>Camps</surname><given-names>SM</given-names></name><name><surname>Karawajczyk</surname><given-names>A</given-names></name><name><surname>Rijs</surname><given-names>AJ</given-names></name><name><surname>Zoll</surname><given-names>J</given-names></name><name><surname>Verweij</surname><given-names>PE</given-names></name><etal/></person-group><article-title>Genotype-phenotype complexity of the TR46/Y121F/T289A cyp51A azole resistance mechanism in <italic>Aspergillus</italic> fumigatus</article-title><source>Fungal Genet Biol</source><year>2015</year><volume>82</volume><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">26092193</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Snelders E, Camps SM, Karawajczyk A, Rijs AJ, Zoll J, Verweij PE, et al. Genotype-phenotype complexity of the TR46/Y121F/T289A cyp51A azole resistance mechanism in <italic>Aspergillus</italic> fumigatus. Fungal Genet Biol. 2015;82:129&#x02013;35.<pub-id pub-id-type="pmid">26092193</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Snelders</surname><given-names>E</given-names></name><name><surname>Karawajczyk</surname><given-names>A</given-names></name><name><surname>Verhoeven</surname><given-names>RJ</given-names></name><name><surname>Venselaar</surname><given-names>H</given-names></name><name><surname>Schaftenaar</surname><given-names>G</given-names></name><name><surname>Verweij</surname><given-names>PE</given-names></name><etal/></person-group><article-title>The structure-function relationship of the <italic>Aspergillus</italic> fumigatuscyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole resistance</article-title><source>Fungal Genet Biol</source><year>2011</year><volume>48</volume><issue>11</issue><fpage>1062</fpage><lpage>1070</lpage><pub-id pub-id-type="pmid">21907818</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Snelders E, Karawajczyk A, Verhoeven RJ, Venselaar H, Schaftenaar G, Verweij PE, et al. The structure-function relationship of the <italic>Aspergillus</italic> fumigatuscyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole resistance. Fungal Genet Biol. 2011;48(11):1062&#x02013;70.<pub-id pub-id-type="pmid">21907818</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Jimenez</surname><given-names>I</given-names></name><name><surname>Lucio</surname><given-names>J</given-names></name><name><surname>Men&#x000e9;ndez-Fraga</surname><given-names>MD</given-names></name><name><surname>Mellado</surname><given-names>E</given-names></name><name><surname>Pel&#x000e1;ez</surname><given-names>T</given-names></name></person-group><article-title>Hospital environment as a source of Azole-Resistant <italic>Aspergillus</italic> fumigatus strains with TR34/L98H and G448S Cyp51A mutations</article-title><source>J Fungi (Basel)</source><year>2021</year><volume>7</volume><issue>1</issue><fpage>22</fpage><pub-id pub-id-type="pmid">33401764</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Gonzalez-Jimenez I, Lucio J, Men&#x000e9;ndez-Fraga MD, Mellado E, Pel&#x000e1;ez T. Hospital environment as a source of Azole-Resistant <italic>Aspergillus</italic> fumigatus strains with TR34/L98H and G448S Cyp51A mutations. J Fungi (Basel). 2021;7(1):22.<pub-id pub-id-type="pmid">33401764</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Atamna</surname><given-names>A</given-names></name><name><surname>Yeshurun</surname><given-names>M</given-names></name><name><surname>Shargian</surname><given-names>L</given-names></name><name><surname>Raanani</surname><given-names>P</given-names></name><name><surname>Kramer</surname><given-names>M</given-names></name><name><surname>Ben Zvi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Fatal invasive pulmonary and cerebral aspergillosis due to triazole-resistant Aspergillus fumigatus with multiple CYP51A mutations</article-title><source>J Antimicrob Chemother</source><year>2024</year><volume>79</volume><issue>5</issue><fpage>1191</fpage><lpage>1192</lpage><pub-id pub-id-type="pmid">38334380</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Atamna A, Yeshurun M, Shargian L, Raanani P, Kramer M, Ben Zvi H, et al. Fatal invasive pulmonary and cerebral aspergillosis due to triazole-resistant Aspergillus fumigatus with multiple CYP51A mutations. J Antimicrob Chemother. 2024;79(5):1191&#x02013;2.<pub-id pub-id-type="pmid">38334380</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Miyazaki</surname><given-names>M</given-names></name><name><surname>Horii</surname><given-names>T</given-names></name><name><surname>Hata</surname><given-names>K</given-names></name><name><surname>Watanabe</surname><given-names>N-a</given-names></name><name><surname>Nakamoto</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><etal/></person-group><article-title>In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds</article-title><source>Antimicrob Agents Chemother</source><year>2011</year><volume>55</volume><issue>10</issue><fpage>4652</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">21825291</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Miyazaki M, Horii T, Hata K, Watanabe N-a, Nakamoto K, Tanaka K, et al. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother. 2011;55(10):4652&#x02013;8.<pub-id pub-id-type="pmid">21825291</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Hata</surname><given-names>K</given-names></name><name><surname>Horii</surname><given-names>T</given-names></name><name><surname>Miyazaki</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>N-a</given-names></name><name><surname>Okubo</surname><given-names>M</given-names></name><name><surname>Sonoda</surname><given-names>J</given-names></name><etal/></person-group><article-title>Efficacy of Oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, <italic>Aspergillosis</italic>, and fusariosis</article-title><source>Antimicrob Agents Chemother</source><year>2011</year><volume>55</volume><issue>10</issue><fpage>4543</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">21788462</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Hata K, Horii T, Miyazaki M, Watanabe N-a, Okubo M, Sonoda J, et al. Efficacy of Oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, <italic>Aspergillosis</italic>, and fusariosis. Antimicrob Agents Chemother. 2011;55(10):4543&#x02013;51.<pub-id pub-id-type="pmid">21788462</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Castanheira</surname><given-names>M</given-names></name><name><surname>Duncanson</surname><given-names>FP</given-names></name><name><surname>Diekema</surname><given-names>DJ</given-names></name><name><surname>Guarro</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>RN</given-names></name><name><surname>Pfaller</surname><given-names>MA</given-names></name></person-group><article-title>Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against fusarium and scedosporium species identified using molecular methods</article-title><source>Antimicrob Agents Chemother</source><year>2012</year><volume>56</volume><issue>1</issue><fpage>352</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">22083469</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Castanheira M, Duncanson FP, Diekema DJ, Guarro J, Jones RN, Pfaller MA. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against fusarium and scedosporium species identified using molecular methods. Antimicrob Agents Chemother. 2012;56(1):352&#x02013;7.<pub-id pub-id-type="pmid">22083469</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Pfaller</surname><given-names>MA</given-names></name><name><surname>Watanabe</surname><given-names>N</given-names></name><name><surname>Castanheira</surname><given-names>M</given-names></name><name><surname>Messer</surname><given-names>SA</given-names></name><name><surname>Jones</surname><given-names>RN</given-names></name></person-group><article-title>Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European committee on antimicrobial susceptibility testing methods</article-title><source>J Antimicrob Chemother</source><year>2011</year><volume>66</volume><issue>11</issue><fpage>2581</fpage><lpage>2584</lpage><pub-id pub-id-type="pmid">21873291</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Pfaller MA, Watanabe N, Castanheira M, Messer SA, Jones RN. Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European committee on antimicrobial susceptibility testing methods. J Antimicrob Chemother. 2011;66(11):2581&#x02013;4.<pub-id pub-id-type="pmid">21873291</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Pfaller</surname><given-names>MA</given-names></name><name><surname>Huband</surname><given-names>MD</given-names></name><name><surname>Flamm</surname><given-names>RK</given-names></name><name><surname>Bien</surname><given-names>PA</given-names></name><name><surname>Castanheira</surname><given-names>M</given-names></name></person-group><article-title>In vitro activity of APX001A (Manogepix) and comparator agents against 1,706 fungal isolates collected during an international surveillance program in 2017</article-title><source>Antimicrob Agents Chemother</source><year>2019</year><volume>63</volume><issue>8</issue><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/aac.00840-19</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Pfaller MA, Huband MD, Flamm RK, Bien PA, Castanheira M. In vitro activity of APX001A (Manogepix) and comparator agents against 1,706 fungal isolates collected during an international surveillance program in 2017. Antimicrob Agents Chemother. 2019;63(8):10&#x02013;1128. 10.1128/aac.00840-19.</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchhoff</surname><given-names>L</given-names></name><name><surname>Dittmer</surname><given-names>S</given-names></name><name><surname>Buer</surname><given-names>J</given-names></name><name><surname>Rath</surname><given-names>PM</given-names></name><name><surname>Steinmann</surname><given-names>J</given-names></name></person-group><article-title>In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus</article-title><source>Int J Antimicrob Agents</source><year>2020</year><volume>56</volume><issue>3</issue><fpage>106105</fpage><pub-id pub-id-type="pmid">32721601</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Kirchhoff L, Dittmer S, Buer J, Rath PM, Steinmann J. In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus. Int J Antimicrob Agents. 2020;56(3):106105.<pub-id pub-id-type="pmid">32721601</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Astvad</surname><given-names>KA-O</given-names></name><name><surname>J&#x000f8;rgensen</surname><given-names>KM</given-names></name><name><surname>Hare</surname><given-names>RA-OX</given-names></name><name><surname>Datcu</surname><given-names>R</given-names></name><name><surname>Arendrup</surname><given-names>MA-O</given-names></name></person-group><article-title>Olorofim susceptibility testing of 1,423 danish mold isolates obtained in 2018&#x02013;2019 confirms uniform and broad-spectrum activity</article-title><source>Antimicrob Agents Chemother</source><year>2020</year><volume>65</volume><fpage>10</fpage><lpage>1128</lpage></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Astvad KA-O, J&#x000f8;rgensen KM, Hare RA-OX, Datcu R, Arendrup MA-O. Olorofim susceptibility testing of 1,423 danish mold isolates obtained in 2018&#x02013;2019 confirms uniform and broad-spectrum activity. Antimicrob Agents Chemother. 2020;65:10&#x02013;1128.</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>J&#x000f8;rgensen</surname><given-names>KM</given-names></name><name><surname>Astvad</surname><given-names>KMT</given-names></name><name><surname>Hare</surname><given-names>RK</given-names></name><name><surname>Arendrup</surname><given-names>MC</given-names></name></person-group><article-title>EUCAST determination of olorofim (F901318) susceptibility of mold species, method validation, and MICs</article-title><source>Antimicrob Agents Chemother</source><year>2018</year><volume>62</volume><issue>8</issue><fpage>10</fpage><lpage>1128</lpage></element-citation><mixed-citation id="mc-CR46" publication-type="journal">J&#x000f8;rgensen KM, Astvad KMT, Hare RK, Arendrup MC. EUCAST determination of olorofim (F901318) susceptibility of mold species, method validation, and MICs. Antimicrob Agents Chemother. 2018;62(8):10&#x02013;1128.</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Buil</surname><given-names>JB</given-names></name><name><surname>Rijs</surname><given-names>A</given-names></name><name><surname>Meis</surname><given-names>JF</given-names></name><name><surname>Birch</surname><given-names>M</given-names></name><name><surname>Law</surname><given-names>D</given-names></name><name><surname>Melchers</surname><given-names>WJG</given-names></name><etal/></person-group><article-title>In vitro activity of the novel antifungal compound F901318 against difficult-to-treat <italic>Aspergillus</italic> isolates</article-title><source>J Antimicrob Chemother</source><year>2017</year><volume>72</volume><issue>9</issue><fpage>2548</fpage><lpage>2552</lpage><pub-id pub-id-type="pmid">28605488</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Buil JB, Rijs A, Meis JF, Birch M, Law D, Melchers WJG, et al. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat <italic>Aspergillus</italic> isolates. J Antimicrob Chemother. 2017;72(9):2548&#x02013;52.<pub-id pub-id-type="pmid">28605488</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Buil</surname><given-names>JB</given-names></name><name><surname>Oliver</surname><given-names>JD</given-names></name><name><surname>Law</surname><given-names>D</given-names></name><name><surname>Baltussen</surname><given-names>T</given-names></name><name><surname>Zoll</surname><given-names>J</given-names></name><name><surname>Hokken</surname><given-names>MWJ</given-names></name><etal/></person-group><article-title>Resistance profiling of Aspergillus fumigatus to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance</article-title><source>Emerg Microb Infect</source><year>2022</year><volume>11</volume><fpage>703</fpage><lpage>714</lpage></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Buil JB, Oliver JD, Law D, Baltussen T, Zoll J, Hokken MWJ, et al. Resistance profiling of Aspergillus fumigatus to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance. Emerg Microb Infect. 2022;11:703&#x02013;14.</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Escribano</surname><given-names>P</given-names></name><name><surname>G&#x000f3;mez</surname><given-names>A</given-names></name><name><surname>Reigadas</surname><given-names>E</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>P</given-names></name><name><surname>Guinea</surname><given-names>J</given-names></name></person-group><article-title>EUCAST-obtained olorofim MICs against <italic>Aspergillus</italic> and scedosporium species and lomentospora prolificans showed high agreements between visual inspection and spectrophotometric readings</article-title><source>Antimicrob Agents Chemother</source><year>2022</year><volume>66</volume><issue>9</issue><fpage>e00849</fpage><lpage>e922</lpage><pub-id pub-id-type="pmid">35924916</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Escribano P, G&#x000f3;mez A, Reigadas E, Mu&#x000f1;oz P, Guinea J. EUCAST-obtained olorofim MICs against <italic>Aspergillus</italic> and scedosporium species and lomentospora prolificans showed high agreements between visual inspection and spectrophotometric readings. Antimicrob Agents Chemother. 2022;66(9):e00849-e922.<pub-id pub-id-type="pmid">35924916</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>